Washington, DC – The Board of Pharmacy Specialties (BPS) is proud to announce the fourth annual recipients of the PGY2 Pharmacy Residency Research Seed Grants as James Hunter Fly, PharmD, and Adam Moss, PharmD. This program offers up to two $5,000 seed grants to PGY2 pharmacy residents who design projects that evaluate the impact of pharmacist board certification on medication-related outcomes for patients, demonstrate the value of board certification for pharmacist specialists to key stakeholder groups (i.e., patients, payers, physicians, and other health care providers), or contribute to credentialing or privileging of pharmacist specialists across practice settings. The grant will go towards completion of their research projects.
“BPS continues to receive many high-quality proposals for Seed Grant funding. The research carried out with support from the BPS Seed Grant project allows residents to contribute to the growing body of literature surrounding the value of pharmacist board certification.” Said BPS Board Chair, Hal Richards, PharmD, BCNSP.
BPS is proud to recognize these researchers and support completion of their work.
James Hunter Fly, PharmD, PGY2 Pediatric Pharmacy Practice Resident at Le Bonheur Children’s Hospital/The University of Tennessee College of Pharmacy was recognized for his proposal: “A qualitative and quantitative investigation of board certification for pharmacists.” Dr. Fly will conduct research in collaboration with Jeremy Stultz, PharmD, BCPPS and Kelly S. Bobo, PharmD, MBA, BCPS, BCPPS.
In his proposal, he wrote:
Successful completion of the rigorous board certification process validates the
recipient has a robust knowledge base, clinical training, and practice experience as a pharmacist. Certification can be in general pharmacotherapy or within a certain specialty, including pediatrics (BCPPS). Little is known regarding perceptions of BCPPS certification. Our central hypothesis is that BCPPS certification differentially impacts perception of pharmacists’ abilities among multiple professionals and types of institutions. We seek to test this hypothesis via the following two aims: Aim 1 of this research proposal is to determine the perceptions and reported impact of pediatric board certification for pharmacists who are providing pharmacotherapy services for pediatric patients. This will be assessed by a combination of a survey and focus group sessions with staff and clinical pharmacists, managerial level pharmacists, nurses, and physicians. Aim 2 will be to compare findings between professionals and between institution type (e.g., free-standing vs non-free-standing hospitals). This will also be assessed by a combination of a survey and focus group sessions. Completion of the two above aims will allow us to define and compare the perceptions of BCPPS certification. These data could be used to further delineate the impact of BCPPS certification.
Adam Moss, PharmD, second year Health-System Pharmacy Administration Fellow at the University of North Carolina Eshelman School of Pharmacy was selected for his proposal: “Evaluation of the percentage and perceived value of board-certified pharmacists in U.S. hospitals and associated impact on clinical and operational measures.” Dr. Moss will conduct research in collaboration with Stephen Eckel, PharmD, MHA and Kathryn Morbitzer, PharmD, MS.
In his proposal, he wrote:
…the requirement for pharmacists to be board-certified in different practice settings is becoming more commonplace. To promote this trend among hospital employers, influence state boards of pharmacy regarding granting privileging status, and provide validation for reimbursement of cognitive and specialized services by pharmacists, developing an evidence base demonstrating the impact of BPS certification for pharmacists can be very helpful. The specific aims of the research are as follows:
- Understand the current percentage, incentive practices and perceived value of board-certified pharmacists in pharmacy departments and pharmacy leadership teams across hospitals (i.e.,academic medical centers, community hospitals) in the U.S.
- Examine the relationship between percentages of board-certified pharmacists in pharmacy departments and quality outcome measures.
- Evaluate whether pharmacy departments have improved financial performance based on percentages of board-certified pharmacists.
This study is proposed as a pilot study. Successful completion of this study may garner further interest from hospitals that are willing to explore the impact of board-certified pharmacists on additional pharmacy inpatient and outpatient measures that involve proprietary data. Therefore, we believe this study is scalable and reproducible, and thus will begin the process of providing constructive validation of BPS-certified pharmacists in the healthcare system nationwide.
“BPS enthusiastically congratulates both teams of investigators for their outstanding proposals and we thank the many other teams who submitted proposals. We look forward to reviewing findings of the projects.” Said BPS Director of Professional Affairs, Ellie LaNou, PharmD.
About the Board of Pharmacy Specialties
The Board of Pharmacy Specialties (BPS) was established in 1976 as an autonomous division of the American Pharmacists Association (APhA). The mission of BPS is to improve patient care by positioning BPS Board-Certified Pharmacist Specialists as integral members of multidisciplinary healthcare teams, through recognition and promotion of specialized training, knowledge, and skills for pharmacists in the United States and internationally. Board certification is a recognized credential for determining which pharmacists are qualified to contribute at advanced practice levels given the rigorous standards mandated by BPS board certification and recertification. BPS currently recognizes more than 51,500 active pharmacist certifications in 14 specialties.
BPS Media Contact
Senior Manager, Social Media & Content Marketing